Overexpression of t-DARPP has been shown to confer resistance to trastuzumab, a HER2-targeted monoclonal antibody, via activation of PKA and PI3K/AKT cell signaling in HER2+ breast cancer cells53,54. Here, ERBB2 is linked to breast carcinoma.